top 20 Renal Disorders

Science & Innovation

 

Advantages of Technology Platform

As a biotech company, Youngen has developed a Fast Integrated Screening Technology called FlSTsiran that is uniquely positioned to rapidly identify RNA molecules with potent activity, long durability and superior safety.

 

Youngen has developed a Multi-targeted Single-entity Technology called MSTsiran  that is capable of incorporating two or more different siRNAs. This technology could be applied to treat many complex diseases that are caused by the dysregulation of more than one gene or multiple diseases.

 

As a center for biological research, Youngen has developed a siRNA Transport Technology called STTsiran that can significantly enhance the activity of siRNA drugs in extra-hepatic tissues. This technology enables tissue specific targeting including the brain, muscle, and adipose.

 

If you want to know more about the progress of technology, new innovation of science and recent developments in biomedical science, please visit our website.

 

We have been engaged in innovation and technology industry for many years, anything you need, please contact us.

 

Technology is all about transforming ideas into tangible solutions that address real-world challenges. It involves the systematic application of scientific knowledge and engineering principles to create tools, systems, and processes that enhance efficiency, improve communication, and drive progress across various sectors. At its core, technology is about problem-solving and innovation, continuously pushing the boundaries of what is possible to make our lives more connected, productive, and sustainable.

 

For more details of cardiovascular diseases treatment, please leave us a message.

 

 

 

Enjoyed this article? Stay informed by joining our newsletter!

Comments

You must be logged in to post a comment.

About Author

Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause disease. Youngen has been dedicating to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general population impacting millions of people around the world. Leveraging these platform technologies, we built diversified product pipelines with globally competitive, first-in-class and best-in-class potential. We’re exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders. https://www.youngenbiomed.com/

Recent Articles
Aug 18, 2026, 9:05 AM youngen
Aug 18, 2026, 9:04 AM youngen
Aug 18, 2026, 9:02 AM youngen